Trump to announce a drug pricing agreement with pharmaceutical company Regeneron: Leavitt

WASHINGTON (TNND) — President Donald Trump is set to announce a drug pricing agreement with pharmaceutical company Regeneron, marking the final deal in a yearlong effort by the Trump administration to push major drugmakers to lower costs.

White House Press Secretary Karoline Leavitt shared the news on social media Thursday afternoon.

Under the agreement, Regeneron will reportedly reduce prices for its current and future medications in Medicaid and offer its cholesterol drug Praluent for a set discounted price through a new federal platform aimed at connecting Americans with lower-cost prescriptions.

The deal is part of Trump’s “Most Favored Nation” initiative, which seeks to align U.S. drug prices with those paid in other developed countries. Regeneron had been the last of 17 pharmaceutical companies targeted by the administration to reach such an agreement.

Citing a source familiar with the deal, NOTUS reported that the company has also committed to investing billions of dollars in domestic manufacturing and will provide a newly approved gene therapy for a rare form of hearing loss free to eligible patients in the U.S..

The White House has made lowering prescription drug costs a central part of its domestic policy agenda, particularly as affordability remains a top concern for voters. However, critics have questioned the impact of the agreements, noting that some of the discounts apply primarily to government programs like Medicaid and may not significantly reduce out-of-pocket costs for all consumers.

Trump’s announcement is scheduled for 3 p.m.